Clinical trials
Metastatic Renal Cell Carcinoma clinical trials
Below are recruiting metastatic renal cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 358 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04989959RecruitingPhase 1
PET/CT scan test in kidney cancer and related conditions
This Phase 1 study tests whether a special PET/CT scan drug ([18F]PT2385) can help doctors see kidney cancer and related tumors. It may help guide diagnosis and treatment decisions, especially in people planning surgery or starting belzutifan.
Dallas, TexasAges 18 years+ - NCT04974671RecruitingPhase 2
SBRT radiation for limited cancer growth on immunotherapy
This trial tests whether targeted external-beam radiation (SBRT) can control a small number of progressing kidney cancer spots while you continue immune checkpoint inhibitor immunotherapy. It may help shrink or stop those specific “oligoprogressive” lesions and prolong benefit from your current immunotherapy.
New Haven, ConnecticutAges 18 years+ - NCT05706129RecruitingPhase 1/Phase 2
Testing targeted imaging and therapy for advanced solid tumors
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
MelbourneAges 18 years+ - NCT05700461RecruitingPhase 1
Testing a new implant drug delivery device for kidney cancer
This early-phase study tests a new small implant (“IMD”) that can deliver a drug for people with kidney cancer going to surgery. If you qualify, you would get the implant placed through the skin and later have it removed during your operation, along with extra lab checks and genetic testing.
Boston, MassachusettsAges 18 years+ - NCT05665361RecruitingPhase 1/Phase 2
Testing palbociclib plus sasanlimab for advanced kidney cancers
This study tests a combination of two medicines—palbociclib and sasanlimab—in people with advanced clear cell or papillary kidney cancer. It’s mainly designed to check safety (and early signs of how well the treatment may work) in these cancer types.
Bethesda, MarylandAges 18–100 - NCT03556228RecruitingPhase 1/Phase 2
Tested medicine for tumors with TrkA changes, alone or with pembrolizumab
This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.
Santa Rosa, CaliforniaAges 18–80 - NCT05361720RecruitingPhase 2
Genetic test to match treatment for advanced kidney cancer
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
Duarte, CaliforniaAges 18 years+ - NCT05327686RecruitingPhase 2
Adding focused radiation to immunotherapy for kidney cancer
This Phase 2 trial studies whether adding focused, high-precision radiation to immunotherapy helps people with advanced kidney cancer (that cannot be removed by surgery or has spread). It aims to improve cancer control by combining two treatment approaches.
Birmingham, AlabamaAges 18 years+ - NCT05263050RecruitingPhase 2
Trial tests a new cabozantinib schedule for kidney and neuroendocrine tumors
This Phase 2 study tests a different dosing schedule of cabozantinib (a cancer medicine) for metastatic kidney cancer and certain neuroendocrine tumors. It aims to see if the timing and schedule can work well for people with advanced disease.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05269381RecruitingPhase 1/Phase 2
Personalized cancer vaccine with pembrolizumab for advanced solid tumors
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
Jacksonville, FloridaAges 16 years+ - NCT05287945RecruitingPhase 1/Phase 2
Orellanine for kidney cancer patients on dialysis
This early-stage study tests orellanine to treat advanced kidney cancer that has spread (metastatic clear-cell or papillary type). It may help by shrinking or controlling cancer, and by seeing whether the treatment is safe and tolerable in people already on chronic dialysis.
Orange, CaliforniaAges 18 years+ - NCT05283226RecruitingPhase 2
Oral anti-cancer pill plus paclitaxel after immunotherapy failure
This Phase 2 trial studies an oral study drug (NRC-2694-A) given with paclitaxel to treat head and neck squamous cell cancer that has come back or spread after immunotherapy. It tests whether this combination is safer and works better than expected for people whose cancer progressed on immune checkpoint inhibitors.
Fullerton, CaliforniaAges 18 years+ - NCT05155033RecruitingPhase 2
A trial of PD-1 plus aldesleukin for melanoma or kidney cancer
This Phase 2 study tests whether combining anti–PD-1 treatment with aldesleukin can shrink or control metastatic melanoma or metastatic kidney (renal cell) cancer. It is mainly for people who have either not had anti–PD-1 before, or whose cancer did not respond to prior anti–PD-1 treatment.
Bethesda, MarylandAges 18–120 - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Phoenix, ArizonaAges 18 years+ - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
San Diego, CaliforniaAges 18 years+ - NCT05127824RecruitingPhase 2
Kidney cancer vaccine made from your own immune cells
This Phase 2 study tests a personalized kidney cancer vaccine made from your own immune cells. It aims to help your immune system recognize and attack clear cell kidney cancer after surgery, potentially lowering the chance of the cancer coming back.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05092373RecruitingPhase 1
Tumor treating device plus targeted or immune drugs for advanced cancers
This Phase 1 study tests whether a tumor treating fields device works better when added to standard cancer drugs. It may help people with advanced solid tumors in the chest or belly, especially when standard treatment didn’t work or can’t be tolerated.
Houston, TexasAges 18 years+ - NCT05024214RecruitingPhase 1/Phase 2
Test of envafolimab plus lenvatinib for advanced solid tumors
This trial studies whether combining envafolimab (an anti-immune cancer medicine) with lenvatinib (a targeted pill) can shrink or control advanced cancers that have stopped responding to standard care. It may help people whose tumors are not curable with usual treatments, by testing a new combo and finding safe doses.
Bengbu, AnhuiAges 18 years+ - NCT05059444Recruiting
Blood test to catch cancer early after treatment
This study looks for signs of cancer left in the body after treatment using a simple blood test (called a liquid biopsy). It aims to see if the test can catch cancer that might come back earlier than regular scans.
Birmingham, AlabamaAges 18 years+ - NCT05023265Recruiting
Study quality of life after SBRT for kidney cancer
This trial studies how well people do—especially their quality of life—after SBRT radiation for primary kidney cancer that can’t be removed with surgery. It may help doctors understand which patients benefit most and what side effects to expect.
Toronto, OntarioAges 18 years+ - NCT05048212RecruitingPhase 2
Nivolumab, ipilimumab, and cabozantinib for kidney cancer brain spread
This Phase 2 study tests how well nivolumab plus ipilimumab, along with cabozantinib, treats untreated or worsening kidney cancer that has spread to the brain. It may help shrink brain tumors and slow the disease when standard local brain treatments aren’t the right option.
Houston, TexasAges 18 years+ - NCT04981119Recruiting
Test apheresis for CAR T manufacturing in HLA-A2 solid tumors
This trial studies how a process called apheresis is used to make CAR T cells for people with certain solid tumors. It is designed for tumors that have lost a specific immune marker (HLA-A*02), which may affect how well CAR T therapies work.
Gilbert, ArizonaAges 18 years+ - NCT04977453RecruitingPhase 1/Phase 2
Study drug GI-101 alone or with immune or blood-pressure meds
This early-phase study tests GI-101 in people with advanced solid cancers. It may be given alone or combined with pembrolizumab or lenvatinib to see how safe it is and whether it can shrink tumors.
New York, New YorkAges 18 years+ - NCT04895709RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
Clovis, CaliforniaAges 18 years+
Hear when a new Metastatic Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic renal cell carcinoma?
- Yes. Clin2 currently lists 358 recruiting metastatic renal cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic renal cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic renal cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Clear Cell Renal Cell Carcinoma
- Clear Cell Renal Cell Carcinoma
- Advanced Clear Cell Renal Cell Carcinoma
- Metastatic Sarcomatoid Renal Cell Carcinoma
- Non-Clear Cell Renal Cell Carcinoma (nccRCC)
- Renal Cell Carcinoma
- Metastatic Lung Non-Small Cell Carcinoma
- Metastatic Head and Neck Squamous Cell Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.